Currently, there is a phase III trial for the use of a combination of the BRAF/MEK inhibitors encorafenib and binimetinib for the adjuvant treatment of BRAF V600-mutant stage IIB/IIC melanomas after complete resection. This evidence concerns the gene MAP2K7 and melanoma.